Premium
Loss of special AT ‐rich sequence‐binding protein 1 ( SATB 1) predicts poor survival in patients with colorectal cancer
Author(s) -
AlSohaily Sam,
Henderson Christopher,
Selinger Christina,
Pangon Laurent,
Segelov Eva,
KohonenCorish Maija R. J.,
Warusavitarne Janindra
Publication year - 2014
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/his.12295
Subject(s) - colorectal cancer , sequence (biology) , cancer , medicine , biology , genetics
Aim Special AT ‐rich sequence‐binding protein 1 ( SATB 1) is a cell type‐specific matrix attachment region binding protein, functioning as a global genome organizer. This study aims to investigate the expression pattern and the prognostic value of SATB 1 in colorectal cancer. Methods and results Prospectively collected data were obtained and tissue microarrays were constructed from a cohort of 352 patients. SATB 1 protein expression was evaluated by immunohistochemistry and scored by two independent investigators. SATB 1 expression was predominantly nuclear in both normal and cancer tissues. Loss of SATB 1 nuclear expression was seen in 22% of colorectal cancers compared to 1.5% of adjacent normal colorectal tissue, and was associated with worse overall survival ( P = 0.02) independent of age and stage of disease ( HR 2.48 with 95% CI 1.31–4.70). Loss of SATB 1 expression was more evident in younger patients ( P = 0.03), tumours with mucinous or signet ring histology ( P = 0.0001) and poor differentiation ( P = 0.005). SATB 1 expression was associated with a survival advantage in patients with Dukes C tumours who received adjuvant chemotherapy. Conclusion Loss of SATB 1 nuclear expression correlates with poor survival and a less favourable response to adjuvant chemotherapy in colorectal cancer. The value of SATB 1 in individualized colorectal cancer therapy warrants further evaluation.